SEB Asset Management AB bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,977,137 shares of the company’s stock, valued at approximately $59,551,000.
Other hedge funds also recently added to or reduced their stakes in the company. Swiss National Bank increased its holdings in Teva Pharmaceutical Industries by 28.7% in the first quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock valued at $127,344,000 after buying an additional 941,700 shares in the last quarter. Dorsey Wright & Associates boosted its stake in shares of Teva Pharmaceutical Industries by 43.8% during the 1st quarter. Dorsey Wright & Associates now owns 75,563 shares of the company’s stock worth $2,276,000 after acquiring an additional 23,030 shares in the last quarter. Zhang Financial LLC grew its holdings in shares of Teva Pharmaceutical Industries by 22.0% in the 1st quarter. Zhang Financial LLC now owns 12,200 shares of the company’s stock worth $367,000 after acquiring an additional 2,200 shares during the period. Cornerstone Planning Group LLC grew its holdings in shares of Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the period. Finally, Catalyst Capital Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $1,232,000. 54.05% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, EVP Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $35.61, for a total transaction of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the sale, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This represents a 25.04% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 465,931 shares of company stock valued at $16,332,989. Company insiders own 0.54% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on TEVA
Teva Pharmaceutical Industries Trading Down 0.7%
Shares of TEVA opened at $32.00 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The stock has a market cap of $36.79 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 3.38 and a beta of 0.86. The firm has a 50 day simple moving average of $33.76 and a 200-day simple moving average of $32.69.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. Equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
